Article

Besifloxacin, a Novel Fluoroquinolone, Has Broad-Spectrum In Vitro Activity against Aerobic and Anaerobic Bacteria

Bausch & Lomb, Inc., 1400 N. Goodman St., Rochester, NY 14609, USA.
Antimicrobial Agents and Chemotherapy (Impact Factor: 4.45). 07/2009; 53(8):3552-60. DOI: 10.1128/AAC.00418-09
Source: PubMed

ABSTRACT The antibacterial spectrum of besifloxacin, a novel fluoroquinolone recently approved for treatment of ocular infections, was studied using 2,690 clinical isolates representing 40 species. Overall, besifloxacin was the most potent agent tested against gram-positive pathogens and anaerobes and was generally equivalent to comparator fluoroquinolones in activity against most gram-negative pathogens. Besifloxacin demonstrated potent, broad-spectrum activity, which was particularly notable against gram-positive and gram-negative isolates that were resistant to other fluoroquinolones and classes of antibacterial agents.

Full-text

Available from: Timothy W Morris, Feb 05, 2014
0 Followers
 · 
169 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Purpose: The aim of the study was to evaluate the safety of besifloxacin ophthalmic suspension 0.6% as antibacterial prophylaxis in the surgical setting. Methods: Two prospective safety surveillance studies were conducted—one in the cataract surgery setting and the other in the laser-assisted in situ keratomileusis (LASIK) surgery setting. Cases from patients aged 18 years and above were eligible for inclusion. In both surveillance studies, data were collected from consecutive cases of routine primary cataract surgery and LASIK surgery, respectively, in which besifloxacin ophthalmic suspension 0.6% or moxifloxacin ophthalmic solution 0.5% was used as the topical perioperative prophylactic antibacterial medication as part of the clinician's routine standard of care. The primary safety endpoint was the incidence of treatment-emergent adverse events (TEAEs). Results: The cataract surgery surveillance study included 485 cases/eyes (besifloxacin, n = 333; moxifloxacin, n = 152), whereas the LASIK surveillance study included 456 cases/eyes (besifloxacin, n = 344; moxifloxacin, n = 112). In the cataract study, only 1 TEAE was reported in a besifloxacin case (mild hypersensitivity/allergic reaction considered possibly related to besifloxacin). No TEAEs were reported in the LASIK study. In both studies, surgical outcomes were similar with both treatments. The frequency of preoperative and/or postoperative dosing was generally lower for besifloxacin than that for moxifloxacin. Conclusions: In prospective safety surveillance studies of patients undergoing cataract extraction or LASIK, TEAEs associated with prophylactic use of besifloxacin ophthalmic suspension 0.6% were rare, and surgical outcomes with besifloxacin were similar to those with moxifloxacin ophthalmic solution 0.5%.
    Cornea 03/2014; 33(5). DOI:10.1097/ICO.0000000000000098 · 2.36 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: AimsIn this study, we investigated the in vitro potential of the bioactive extracts from five putatively novel species of actinomycetes isolated from the Indian hot desert against multi-drug resistant Streptococcus pneumoniae.Methods and ResultsThe antimicrobial activity of 10 different extracts was evaluated against Streptococcus pneumoniae strains with, erm(B) and mef(E) genes as well as fluoroquinolone resistant (FQR) strains using the micro broth dilution method. Of these 10 extracts, 4 exhibited good to excellent anti-Streptococcus pneumoniae activity with minimum inhibitory concentrations (MICs) ranging from 0.125 μg ml−1 to 8 μg ml−1. The time–kill kinetics study showed that these extracts killed the pathogens in 2–8 h. In vitro cell free transcription/translation of luciferase gene using S30 bacterial extract and TNT mammalian ribosome indicated that they inhibited bacterial ribosomes at much lower concentrations than those required to inhibit the mammalian ribosomes.Conclusions This study demonstrates that these are potent concentration-dependent bactericidal metabolites with 16 fold higher in vitro activity than levofloxacin against multi-drug resistant Streptococcus pneumoniae.Significance and Impact of StudyMetabolites from actinomycetes can be excellent inhibitors of multi-drug resistant S. pneumoniae. Considering the in vitro efficacy of these crude extracts against S. pneumoniae MDR spp., once purified these can be used against streptococcal pathogens causing community-acquired pneumonia.This article is protected by copyright. All rights reserved.
    Journal of Applied Microbiology 03/2015; 118(6). DOI:10.1111/jam.12810 · 2.39 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Abstract Purpose: The objective of this study was to collect and evaluate retrospective safety information about the use of besifloxacin ophthalmic suspension 0.6% for the treatment of bacterial keratitis. Methods: This was a retrospective, postmarketing surveillance study conducted at 10 clinical centers in the United States. The study population included 142 patients treated with besifloxacin ophthalmic suspension 0.6% for bacterial keratitis in one or both eyes. For perspective, data on 85 patients treated at these centers with moxifloxacin ophthalmic solution 0.5% for bacterial keratitis were also included. The analysis was designed to measure the types and rates of adverse events (AEs) reported during the treatment of bacterial keratitis with besifloxacin ophthalmic suspension 0.6%. Other treatment outcomes of interest included the development of corneal scarring and corneal neovascularization, measured or presumed bacterial eradication, ending visual acuity, and duration of pain before and after treatment. Results: There was one reported AE of mild superficial punctate keratitis in a patient using besifloxacin ophthalmic suspension 0.6%. The difference in AE frequencies between groups was not significant (P>0.999). Additional treatment outcomes were similar for both groups. Limitations of this report include the retrospective nature of the study. Conclusions: These retrospective data suggest that besifloxacin ophthalmic suspension 0.6% was well tolerated when included in the treatment of bacterial keratitis; no serious AEs were reported. A prospective clinical trial is needed to better isolate the contribution of besifloxacin to the therapeutic outcome and to confirm these observations.
    Journal of Ocular Pharmacology and Therapeutics 11/2014; 31(2). DOI:10.1089/jop.2014.0039 · 1.42 Impact Factor